- Home
- STRO vs IGMS Comparison
STRO vs IGMS Comparison
Compare STRO & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- IGMS
- Stock Information
- Founded
- STRO 2003
- IGMS 1993
- Country
- STRO United States
- IGMS United States
- Employees
- STRO N/A
- IGMS N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- IGMS Health Care
- Exchange
- STRO Nasdaq
- IGMS Nasdaq
- Market Cap
- STRO 77.7M
- IGMS 81.9M
- IPO Year
- STRO 2018
- IGMS 2019
- Fundamental
- Price
- STRO $0.88
- IGMS $1.26
- Analyst Decision
- STRO Hold
- IGMS Hold
- Analyst Count
- STRO 7
- IGMS 8
- Target Price
- STRO $3.97
- IGMS $6.00
- AVG Volume (30 Days)
- STRO 513.9K
- IGMS 675.3K
- Earning Date
- STRO 08-12-2025
- IGMS 08-13-2025
- Dividend Yield
- STRO N/A
- IGMS N/A
- EPS Growth
- STRO N/A
- IGMS N/A
- EPS
- STRO N/A
- IGMS N/A
- Revenue
- STRO $66,434,000.00
- IGMS $2,681,000.00
- Revenue This Year
- STRO N/A
- IGMS $252.44
- Revenue Next Year
- STRO N/A
- IGMS $46.48
- P/E Ratio
- STRO N/A
- IGMS N/A
- Revenue Growth
- STRO N/A
- IGMS 27.36
- 52 Week Low
- STRO $0.52
- IGMS $0.92
- 52 Week High
- STRO $5.17
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- STRO 57.66
- IGMS 47.15
- Support Level
- STRO $0.83
- IGMS $1.25
- Resistance Level
- STRO $1.01
- IGMS $1.29
- Average True Range (ATR)
- STRO 0.07
- IGMS 0.02
- MACD
- STRO 0.01
- IGMS -0.01
- Stochastic Oscillator
- STRO 51.67
- IGMS 8.70
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.